^
Association details:
| Biomarker: | KIT exon 11 mutation + KIT exon 17 mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
Excerpt:
Of interest, two samples demonstrated two mutations: a primary KIT exon 11 mutation with KIT secondary exon 17 mutation, which included the patient with prolonged stable disease
DOI:
10.1007/s00280-011-1785-7
